Clinical Trials Logo

Cicatrix clinical trials

View clinical trials related to Cicatrix.

Filter by:

NCT ID: NCT04756882 Active, not recruiting - Clinical trials for Hypertrophic Scarring

Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars

Start date: November 18, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Background: Scars widen when the overlying musculature pulls apart suture lines. Because Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces temporary muscle paralysis, the purpose of this current study is to evaluate the beneficial effects of Botulinum toxin type A (BTA) on scar formation. Aim of this study: The aim of this study is to evaluate the efficacy and safety of early postoperative Botulinum Toxin type A (BTA) injection on improving vertical or oblique facial surgical scars. Materials and methods: Patients with vertical or oblique forehead lacerations, treated by primary closure, will be enrolled in this study and randomized into two groups: One group (n =6) will receive BTA injection within 5 days of primary closure and the other group (n = 6) will receive no further treatment. Vancouver scar scale (VSS) Scores and wound width will be determined at the 1, 3 and 6 months follow-up visits, along with clinical photographs. Results: Data will be collected, tabulated and statically analyzed. Key words: Botulinum Toxin Type A; facial scarring; wound healing; scar maturation

NCT ID: NCT04736251 Recruiting - Scar Clinical Trials

Mechanistic Basis of Ablative Carbon Dioxide Laser in Treating Hypertrophic Scars

SMOOTH
Start date: December 9, 2019
Phase:
Study type: Observational

This is an observational cohort study which will look at the biomarkers from blood and tissue sample for adult patients with hypertrophic scarring due to burns/trauma incident over 12 months from date of recruitment. The study will assess the kinetics of the response to fractionated carbon dioxide laser therapy in hypertrophic scars.

NCT ID: NCT04722705 Recruiting - Scar Prevention Clinical Trials

Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The scar site was divided into 3 sites; combined IPL/fractional Er:YAG laser treatment site, fractional Er:YAG laser treatment site and untreated control site. At baseline, three lesions were randomized to IPL / fractional Er:YAG laser combination therapy site, fractional Er:YAG laser treatment alone site, and untreated control site. The laser treatment was conducted total three sessions, immediately at suture removal (baseline), 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment (20 weeks after suture removal).

NCT ID: NCT04707131 Completed - Cicatrix Clinical Trials

A Study of Single Ascending Dose of LEM-S401 in Healthy Participants

Start date: July 11, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.

NCT ID: NCT04654507 Recruiting - Clinical trials for Chronic Renal Failure

Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children

Start date: March 3, 2021
Phase: Phase 3
Study type: Interventional

Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with serious complications as hypertension, preeclampsia, and end stage renal failure in young age . So, this study aims to determine whether dexamethasone reduces the renal scarring in children will be treated with antibiotics for acute pyelonephritis. investigators propose to conduct a multi center, randomized, placebo-controlled, double-blind clinical trial, that will evaluate the efficacy of dexamethasone (0.3 mg/kg every 12 hours per day orally for 3 days) in preventing renal scarring in young febrile children (2 months to 14 years) with a first-diagnosed UTI. 120 Participants will be enrolled over a 3-year period from 6 sites.

NCT ID: NCT04619589 Completed - Hypertrophic Scar Clinical Trials

Characterization of Dyschromic Hypertrophic Scar

Start date: May 21, 2019
Phase:
Study type: Observational

Currently, there are limited prevention or treatments available for dyschromia in burn hypertrophic scars (HTSs). The limited available techniques involve transferring melanocytes from unaffected areas to the scar to adjust pigment. These techniques involve the creation of a donor site and do not utilize the cells that may already be present in scars. This study aims to confirm melanocyte presence in regions of hypo- and hyper- pigmented HTS. If melanocytes can be found in regions of hypopigmentation, these scars may be able to be treated in the future by pigmentation stimulators without the need for surgery. Additionally, if pigmentation specific molecules of interest can be found to be up-regulated in hyperpigmented scar, these may be able to be altered by a pharmacotherapy.

NCT ID: NCT04593706 Not yet recruiting - Keloid Clinical Trials

Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids and hypertrophic Scars)

NCT ID: NCT04558944 Completed - Clinical trials for Cicatrix, Hypertrophic

The Effect of Extracorporeal Shock Wave Therapy in the Treatment of Post Burn Scars

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

A prospective, randomized, controlled study. The patients were divided into two groups with twenty patients per group. The control group received the standard treatment for postburn scars. The treatment group received the standard treatment and treatment of postburn scars with Extracorporeal Shock Wave Therapy 512 impulses of 0.15mJ/mm 2 in each session, twice per week for 4 weeks. The investigators assessed the appearance of scar with the Vancouver Scar Scale (VSS), pruritus and pain with Visual Analog Scale (VAS) before the start of the treatment and at 2 weeks and 5 months after the treatment.

NCT ID: NCT04506255 Recruiting - Scar Clinical Trials

Silicone Taping for the Improvement of Abdominal Donor Site Scars

Start date: November 16, 2020
Phase: N/A
Study type: Interventional

This study will look at silicone tape compared to the current no dressing standard at the investigators institution, to determine if silicone tape provides a significant improvement in post-abdominoplasty scar appearance. Silicone tape will be added to half of the abdominoplasty incision of patients undergoing abdominally-based breast reconstruction procedures two weeks after their operation. They will be followed up and assessed at specific timepoints to determine whether the silicone improves scar outcomes in these patients.

NCT ID: NCT04490213 Completed - Clinical trials for Donor Site Complication

Scarring At Donor Sites After Split-Thickness Skin Graft.

Start date: June 15, 2018
Phase:
Study type: Observational

The aim of this study was to investigate if previous findings on the association between dressing treatments and subjective opinion on final donor site scar outcome using the patient scale of POSAS could be confirmed objectively. Scar outcome measurements were assessed by a blinded observer using POSAS and the device: Cutometer dual MPA 580 (Courage and Khazaka Electronic GmbH, Cologne, Germany) to measure the viscoelasticity of the skin.